CrushSCI.com
Journal Selection & Manuscript Polishing Services
AMERICAN JOURNAL OF HEMATOLOGY journal cover Medicine
Back to journal directory

Review Cycle Records

AMERICAN JOURNAL OF HEMATOLOGY

Wiley SCIE Non-OA
2026 Emerging Zone 12025 CAS Zone 1 TOP2025 JCR Q1
62.0Average days
49Median days
3Fastest days
236Longest days
3842025 publications

Paper Review Records

All Paper Review Records

20 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.

33 days

p53 Immunohistochemistry Is a Reliable Method for Assessing TP53 Allelic and Functional Status in TP53 ‐Mutated Cases

AuthorsHong Fang; Joseph D. Khoury; Zhenya Tang; Sa A. Wang; Courtney D. DiNardo; Sanam Loghavi; Wei J. Wang; Yiannis Petros Dimopoulos; Shimin Hu; C. Cameron Yin; Siba El Hussein; Hui Zhang; Jayastu Senapati; Kelly Chien; Michael Andreeff; L. Jeffrey Medeiros; Wei Wang

Affiliations1. Department of Hematopathology University of Texas MD Anderson Cancer Center Houston Texas USA; 2. Department of Pathology, Microbiology and Immunology University of Nebraska Medical Center Omaha Nebraska USA; 3. Department of Leukemia University of Texas MD Anderson Cancer Center Houston Texas USA; 4. Department of Pathology University of Vermont Larner College of Medicine Burlington Vermont USA

Source PDF DOI Publisher page
63 days

EIF2AK1 As a Key Genetic Determinant of Luspatercept Resistance in Transfusion‐Dependent Thalassemia

AuthorsAnthony Iscaro; Simona Leoni; Filippo Russo; Valentina Brancaleoni; Barbara Eleni Rosato; Roberta Marra; Antonella Nostroso; Natalia Scaramellini; Daniele Lello Panzieri; Iris Villa; Teresa Ceglie; Carmen Maria Gaglioti; Neha Kargutkar; Vito Alessandro Lasorsa; Mario Capasso; Giovanni Battista Ferrero; Immacolata Andolfo; Irene Motta; Roberta Russo

Affiliations1. Dipartimento di Medicina Molecolare e Biotecnologie Mediche Università degli Studi di Napoli Federico II Naples Italy; 2. CEINGE Biotecnologie Avanzate Franco Salvatore Naples Italy; 3. Dipartimento di Scienze Cliniche e di Comunità, Dipartimento di Eccellenza 2023–2027 University of Milan Milan Italy; 4. SC Medicina ad Indirizzo Metabolico, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico Milan Italy; 5. University of Milan Milan Italy; 6. Department of Clinical and Biological Sciences University of Turin Turin Italy

Source PDF DOI Publisher page
3 days

Myelodysplastic Syndromes: 2026 Update on Diagnosis, Risk‐Stratification and Management

AuthorsGuillermo Garcia‐Manero

Affiliations1. Department of Leukemia University of Texas MD Anderson Cancer Center Houston Texas USA

Source PDF DOI Publisher page
9 days

Undetectable Hydroxyurea Levels in the Majority of Sickle Cell Disease Patients, Especially in Young Children

AuthorsSigrid van der Veen; Bart J. Biemond; Marjon H. Cnossen; Pablo Bartolucci; Maria P. Boaro; Betzabel Cajiao Garcia; Raffaella Colombatti; M. D'Agnolo; Karin Fijnvandraat; Anna Collado Gimbert; Amira Idrizovic; Petros Kountouris; Mar Mañú‐Pereira; Elisabetta Mezzalira; Mariane de Montalembert; Erfan Nur; A. Pham Hung D' Alexandry D'Orengiani; Tiziana Sanavia; Saskia E. M. Schols; Marissa J. M. Traets; Minke A. E. Rab; Sara I. Reidel; Anita W. Rijneveld; Yosr Zaouali; Nanda M. Verhoeven‐Duif; Judith J. M. Jans; Eduard J. van Beers

Affiliations1. Center for Benign Hematology, Thrombosis and Hemostasis – Van Creveldkliniek, University Medical Center Utrecht, Utrecht University Utrecht the Netherlands; 2. Section Metabolic Diagnostics, Department of Genetics University Medical Centre Utrecht, Utrecht University Utrecht the Netherlands; 3. Department of Hematology Amsterdam University Medical Center Amsterdam the Netherlands; 4. Department of Pediatric Hematology and Oncology, Erasmus MC ‐ Sophia Children's Hospital Erasmus University Medical Center Rotterdam Rotterdam the Netherlands; 5. University Paris‐Est‐Créteil, IMRB, Inserm U955, Henri Mondor University Hospitals, APHP, Sickle Cell Referral Center‐UMGGR Creteil France; 6. UOC Oncoematologia Pediatrica, Azienda Ospedale‐Università Padova Padua Italy; 7. Department of Women's and Children's Health University of Padua Padua Italy; 8. Department of Pediatric Hematology Amsterdam UMC, Emma Children's Hospital Amsterdam the Netherlands; 9. Sanquin Research, Department of Molecular Cellular Hemostasis Amsterdam the Netherlands; 10. Rare Anemia Research Laboratory, Vall D'hebron Institut de Recerca Barcelona Spain; 11. Pediatric Oncology and Hematology Department Hospital Universitari Vall D'hebron Barcelona Spain; 12. Genetics and Microbiology Department Universitat Autonoma de Barcelona Barcelona Spain; 13. Molecular Genetics Thalassaemia Department The Cyprus Institute of Neurology and Genetics Nicosia Cyprus; 14. Department of General Pediatrics and Pediatric Infectious Diseases Sickle Cell Center, Necker‐Enfants Malades Hospital Neuilly France; 15. Department of Blood Cell Research Sanquin Research and Landsteiner Laboratory Amsterdam the Netherlands; 16. AI and Computational Biomedicine Unit, Department of Medical Sciences University of Torino Turin Italy; 17. Department of Hematology Radboud University Medical Center Nijmegen the Netherlands; 18. Central Diagnostic Laboratory ‐ Research, University Medical Center Utrecht Utrecht the Netherlands; 19. Department of Hematology Erasmus University Medical Center Rotterdam the Netherlands

Source PDF DOI Publisher page
67 days

High Proportion of PNH Type II Neutrophils Is Associated With Thrombosis in Patients Displaying a PNH Clone ≥ 1%

AuthorsOrianne Wagner‐Ballon; Anne‐Catherine Lhoumeau; Anna Raimbault; Camille Debord; Jean‐Philippe Vial; Valérie Soenen; Mélanie Pannetier; Edouard Bonneville; Elsa Bera; Caroline Bret; Nicolas Chapuis; Véronique Latger‐Cannard; Caroline Mayeur‐Rousse; Véronique Harrivel; François Vergez; Marie Loosveld; Juliette Vo Xuan; Stéphanie Mathis; Gérard Socié; Flore Sicre de Fontbrune; Régis Peffault de Latour; Bernard Drenou; Agathe Debliquis; Magali Le Garff‐Tavernier; the French PNH working group CytHem‐HPN

Affiliations1. Département Hématologie et Immunologie Biologiques APHP Hôpitaux Universitaires Henri Mondor Créteil France; 2. Université Paris‐Est Créteil (UPEC), Inserm U955 IMRB Créteil France; 3. Institut Paoli Calmettes, Laboratoire de Biopathologie Marseille France; 4. APHP Hôpital Saint Louis, Service Hématologie Biologique Paris France; 5. CHU Nantes, Laboratoire Hématologie Nantes France; 6. CHU Bordeaux, Laboratoire Hématologie Bordeaux France; 7. CHU Lille, Laboratoire Hématologie Lille France; 8. CHU de Rennes, Laboratoire Hématologie Rennes France; 9. CHU Grenoble, Laboratoire Hématologie Grenoble France; 10. CHU Rouen, Laboratoire Hématologie Rouen France; 11. CHU Montpellier, Laboratoire Hématologie Montpellier France; 12. APHP CHU Cochin, Laboratoire Hématologie Paris France; 13. CHU Nancy, Laboratoire Hématologie Nancy France; 14. CHU Strasbourg, Laboratoire Hématologie Strasbourg France; 15. CHU Amiens, Laboratoire Hématologie Amiens France; 16. CHU Toulouse, Laboratoire Hématologie Toulouse France; 17. CHU Timone, Laboratoire Hématologie Marseille France; 18. APHP Hôpital Saint Louis, Service Hématologie Clinique Paris France; 19. Groupe Hospitalier de la Région Mulhouse Sud Alsace Service Hématologie Clinique Mulhouse France; 20. Groupe Hospitalier de la Région Mulhouse Sud Alsace Laboratoire Hématologie Mulhouse France; 21. APHP Groupe Hospitalier Pitié‐Salpêtrière‐Charles Foix, Sorbonne Université Service D'hématologie Biologique Paris France; 22. Centre de Recherche Des Cordeliers, Sorbonne Université, Université Paris Cité, Inserm UMRS 1138 Drug Resistance in Hematological Malignancies Team Paris France

Source PDF DOI Publisher page
61 days

Signaling Mutations Negate the Favorable Impact of NPM1 Mutations in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Treated With VEN / HMA

AuthorsFieke W. Hoff; Joshua F. Zeidner; Geeta Torlapati; Deedra Nicolet; Krzysztof Mrózek; Ying Huang; Alexander Li; Rina Li Welkie; Ronan T. Swords; Elie Traer; Eytan M. Stein; Tara L. Lin; Maria R. Baer; Vu H. Duong; William G. Blum; Martha L. Arellano; Wendy Stock; Olatoyosi Odenike; Rebecca L. Olin; Catherine C. Smith; Gary J. Schiller; Emily K. Curran; Onyee Chan; Christine McMahon; Michael Hochman; Kieran Sahasrabudhe; Charles Foucar; Jesus Gonzalez‐Lugo; Brittany Knick Ragon; Shivani V. Handa; Nyla A. Heerema; Timothy Chen; Molly Martycz; Mona Stefanos; Sonja G. Marcus; Leonard Rosenberg; Brian J. Druker; Ross L. Levine; Amy Burd; Ashley O. Yocum; Uma M. Borate; Alice S. Mims; Ann‐Katrin Eisfeld; John C. Byrd; Yazan F. Madanat

Affiliations1. National Heart, Lung, and Blood Institute National Institutes of Health Bethesda Maryland USA; 2. Division of Hematology, Department of Medicine, Lineberger Comprehensive Cancer Center University of North Carolina Chapel Hill North Carolina USA; 3. The James Cancer Hospital The Ohio State University Columbus Ohio USA; 4. Clara D. Bloomfield Center for Leukemia Outcomes Research The Ohio State University Comprehensive Cancer Center Columbus Ohio USA; 5. Department of Internal Medicine University of Texas Southwestern Medical Center Dallas Texas USA; 6. Division of Hematology and Medical Oncology, Knight Cancer Institute Oregon Health & Science University Portland Oregon USA; 7. Leukemia Service, Department of Medicine, Human Oncology and Pathogenesis Program Memorial Sloan Kettering Cancer Center New York New York USA; 8. Division of Hematologic Malignancies University of Kansas Medical Center Kansas City Kansas USA; 9. Department of Medicine University of Maryland Greenebaum Comprehensive Cancer Center Baltimore Maryland USA; 10. Department of Hematology and Medical Oncology Winship Cancer Institute of Emory University Atlanta Georgia USA; 11. Section of Hematology/Oncology University of Chicago Chicago Illinois USA; 12. Division of Hematology and Oncology University of California, San Francisco San Francisco California USA; 13. Department of Medicine, Hematology/Oncology David Geffen School of Medicine at University of California, Los Angeles Los Angeles California USA; 14. Division of Hematology & Oncology University of Cincinnati Cincinnati Ohio USA; 15. Malignant Hematology Department H. Lee Moffitt Cancer Center Tampa Florida USA; 16. Division of Hematology, Department of Medicine University of Colorado School of Medicine Aurora Colorado USA; 17. Division of Hematology University of Wisconsin, Carbone Cancer Center Madison Wisconsin USA; 18. Department of Internal Medicine, Division of Hematology and Oncology University of New Mexico Albuquerque New Mexico USA; 19. Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health Wake Forest University School of Medicine Charlotte North Carolina USA; 20. Blood Cancer United Washington DC USA; 21. UPMC Hillman Cancer Center University of Pittsburgh Pittsburgh Pennsylvania USA

Source PDF DOI Publisher page
83 days

Comparative Efficacy of Intranasal, Intramuscular, and Intravenous Vitamin B12 Therapy for Hematological Recovery in Vitamin B12 Deficiency Anemia: A Randomized Controlled Trial

AuthorsSantosh Kumar Singh; Rahil Arora; Suman Kumar Pramanik; Abhishek Kumar; Alok Singh; Shantanu Khanna; Nitya Malhotra; Pranay Juneja; Netri Upadhyay; Uday Yanamandra

Affiliations1. Department of Internal Medicine Armed Forces Medical College (AFMC) Pune India; 2. Department of Medical Research Armed Forces Medical College (AFMC) Pune India; 3. Department of Medicine Military Hospital Kirkee Pune India; 4. Department of Radiology Command Hospital, Air Force Bangalore India; 5. Department of Medicine, Government Medical College and Hospital Chandigarh India; 6. Department of Medicine, JNMC, DMIHER Wardha India

Source PDF DOI Publisher page
30 days

Clinical Predictors of Response in Chronic Graft‐Versus‐Host Disease: Results From the “Predicting the Quality of Response to Specific Treatments ( PQRST )” Trial

AuthorsBetty K. Hamilton; Lynn Onstad; Paul A. Carpenter; Joseph Pidala; George Chen; Corey Cutler; Najla El Jurdi; Nosha Farhadfar; Mark Juckett; Carrie L. Kitko; Catherine J. Lee; Stephanie J. Lee

Affiliations1. Blood and Marrow Transplant Program, Department of Hematology and Medical Oncology Taussig Cancer Institute, Cleveland Clinic Cleveland Ohio USA; 2. Clinical Research Division Fred Hutchinson Cancer Center Seattle Washington USA; 3. H. Lee Moffitt Cancer Center and Research Institute Tampa Florida USA; 4. University of Texas MD Anderson Cancer Center Houston Texas USA; 5. Dana Farber Cancer Institute Boston Massachusetts USA; 6. National Cancer Institute, National Institutes of Health Bethesda Maryland USA; 7. Sarah Cannon Transplant and Cellular Program, Methodist Hospital San Antonio Texas USA; 8. University of Minnesota Minneapolis Minnesota USA; 9. Vanderbilt University Medical Center Nashville Tennessee USA

Source PDF DOI Publisher page
236 days

Relapse Thresholds (12/24 Mo) Define Survival Disparity in Pediatric B‐ ALL

AuthorsBinjun Xiong; Jianwen Zhou; Xuhan Zhang; Yance Feng; Jie Cheng; Hui Shi; Qian Li; Wenli Tang; Yali Shen; Fen Zhou; Shaoyan Hu; Hua You

Affiliations1. Precision Oncology and Intelligent Theranostics Laboratory Children's Hospital of Chongqing Medical University Chongqing China; 2. Ministry of Education Key Laboratory of Child Development and Disorders National Clinical Research Center for Children and Adolescents' Health and Diseases Chongqing China; 3. Department of Hematology and Oncology Children's Hospital Affiliated to Zhengzhou University (Zhengzhou Children's Hospital) Zhengzhou China; 4. Division of Life Sciences and Medicine, Department of Pediatric Hematology and Oncology The First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Hospital), University of Science and Technology of China Hefei China; 5. Department of Hematology and Oncology Anhui Provincial Children's Hospital Hefei China; 6. Department of Pediatric Hematology and Oncology Children's Hospital of Chongqing Medical University Chongqing China; 7. Department of Pediatrics Union Hospital, Tongji Medical College of Huazhong University of Science and Technology Wuhan China; 8. Department of Hematology and Oncology Children's Hospital of Soochow University Suzhou China; 9. Department of Pediatric Oncology Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China Chengdu China

Source PDF DOI Publisher page
54 days

Quizartinib in Combination With FLAG ‐ IDA for Relapsed or Refractory Acute Myeloid Leukemia ( FLAG ‐ QUIDA ): A PETHEMA Phase I‐ II Trial

AuthorsTeresa Bernal; Javier Zambrano Márquez; Rebeca Rodríguez‐Veiga; Eduardo Rodríguez‐Arbolí; Juan Manuel Bergua‐Burgués; Susana Vives; Montserrat Arnán; Pilar Martínez Sánchez; Pilar Herrera‐Puente; Josefina Serrano‐López; Vicente Rubio; Inmaculada Marchante‐Cepillo; Marta Cervera‐Calvo; Andrés Novo García; Rosa Fernández Martín; Cristina Gil Cortés; Carlos Rodríguez‐Medina; Victor Noriega‐Concepción; Ana Alfonso‐Piérola; Carmen Loredo; María Antuña‐Casal; Blanca Boluda; Isabel Cano‐Ferri; Evelyn Acuña‐Cruz; Laura Torres‐Miñana; Joaquín Sánchez‐García; Cristina Bilbao; Maria Teresa Gómez‐Casares; David Martínez Cuadrón; Pau Montesinos

Affiliations1. Servicio de Hematología Hospital Universitario Central de Asturias Oviedo Spain; 2. Instituto de Investigación Sanitaria del Principado de Asturias Oviedo Spain; 3. Instituto Universitario de Oncología del Principado de Asturias Oviedo Spain; 4. Servicio de Hematología Hospital Universitario San Agustín de Avilés Avilés Spain; 5. Servicio de Hematología Hospital U. La Fe Valencia Spain; 6. Servicio de Hematología Hospital Universitario Virgen del Rocío, Instituto de Biomedicina de Sevilla (IBIS/CSIC), Universidad de Sevilla Sevilla Spain; 7. Servicio de Hematología Hospital San Pedro de Alcántara Cáceres Spain; 8. Servicio de Hematología, ICO Badalona‐Hospital Universitari Germans Trias i Pujol, Institut de Recerca Josep Carreras Badalona Spain; 9. Servicio de Hematología, Institut Catalá D'oncologia Hospitalet del Llobregat Barcelona Spain; 10. Servicio de Hematología Hospital U. 12 de Octubre Madrid Spain; 11. Servicio de Hematología Hospital Ramón y Cajal Madrid Spain; 12. Servicio de Hematología Hospital Reina Sofía, Córdoba, IMIBIC, UCO Córdoba Spain; 13. Servicio de Hematología Hospital Jerez de la Frontera Jerez de la Frontera Spain; 14. Servicio de Hematología Hospital Juan XXIII Tarragona Spain; 15. Servicio de Hematología Hospital Son Espasses Palma de Mallorca Spain; 16. Servicio de Hematología Hospital Insular Materno‐Infantil Las Palmas de Gran Canaria Spain; 17. Servicio de Hematología Hospital General de Alicante Alicante Spain; 18. Servicio de Hematología Hospital Negrín Las Palmas de Gran Canaria Spain; 19. Servicio de Hematología Hospital Complejo Universitario A Coruña Spain; 20. Servicio de Hematología Clínica Universitaria de Navarra Pamplona Spain; 21. Unidad de Investigación y Docencia Hospital Universitario Central de Asturias Oviedo Spain; 22. Departamento de Medicina Universitat de València Valencia Spain

Source PDF DOI Publisher page

Expert Matching · Case Demo

Turn Your Submission Goalsinto a Verifiable Journal Plan

Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.

CrushSCI online

Client

I work in environmental engineering and need an SCI paper published within three months. I have no grant funding or prominent co-author. Which journals could I target?

CrushSCI

Yes. We will first screen for feasibility against the 90-day deadline, then identify comparable papers without grant support or prominent co-authors. The final shortlist will prioritize research quality and journal scope.

Suggested title
Machine Learning and Life-Cycle Assessment for Predicting and Optimizing Carbon Emissions in Urban Wastewater Treatment

SampleLatest 5 valid paper samples from 2026

Average review96.4 days

Median77 days

Contact CrushSCI

Contact CrushSCI

Leave your contact details so we can discuss your manuscript, editing needs, and submission plan.

Selected service: Paper Editing Service

Or leave your contact details

WhatsApp, Telegram, WeChat, and email are all optional, but at least one is required. Once received, we will contact you as soon as possible.